
    
      Busulfan is a highly toxic drug with narrow therapeutic window used for the conditioning of
      hematopoietic stem cell transplantation. High exposure is associated with systemic toxicity
      such as veno-occlusive disease (VOD) and underexposure is associated with graft failure or
      relapse. In this study the investigators plan to improve the outcome of hematopoietic stem
      cell transplantation by using optimal busulfan dose through pharmacokinetic study.
    
  